Carcinoid tumors and DXA assessment – a study in 222 menopausal women C.Poiana 1,2, M.Carsote 1,2, R.Petris1, R.Trifanescu 1,2, G.Voicu2, D.Paun 1,2 1-Carol Davila University of Medicine and Pharmacy, Bucharest, Romania 2-Parhon national Institute of Endocrinology, Bucharest, Romania   PP152 Introduction The Bone Mineral Density loss may be related to cancer. A specific correlation in the neuroendocrine tumors (NET) is not fully described yet. Aim We analyze DXA in patients with or without NET. Material and Method We perfomed central DXA (spine and hip) with a GE Lunar device in post-menopausal women. None of them were previously treated with anti-osteoporosisdrugs. The study groups included women with carcinoid tumors (pathological confirmation of the diagnosis) and clinical symptoms of the carcinoid syndrome. This is a transversal study. Results 22 patients with confirmed symptomatically carcinoid tumors were included. The control group consisted in 200 carcinoid free women. The two groups were age-matched: mean age was 57 vs. 56.77 yrs (p=NS) The two groups were Body Mass Index - matched: mean BMI was 23.61 vs. 24.01 kg/m2 (p=NS). % of patients with WHO DXA groups DXA BMD (g/cm2) Carcinoid patients Carcinoid free patients p=0.9 Discussions The interpretation of this data is limited to the small number of women with carcinoid tumors. Conclusions Based on our observations, the DXA-BMD was not statistically significant different in women with carcinoid tumors to non-carcinoid tumors patients. Probably the skeletal assessment in these women is a multi-factorial equation, including not only age, BMI, BMD but different other parameters as 25-OH vitamin D levels, etc.